The news is a welcome change for Novavax, which has faced chronic delivery delays. In fact, challenges to deliver its Covid-19 vaccine have weighed on NVAX stock. One big hurdle that remains for Novavax is regulatory approval in the U.S. To date, its vaccine has not received authorization from the U.S. Food and Drug Administration.